Alliance Growers Corp. (CSE:ACG) (“Alliance Growers” or the “Company”) is pleased to report that it has executed the exclusive agreement to acquire the licensed producer applicant, BiocannaTech Inc. (“BiocannaTech”), to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec. Closing will be on or before April 25, 2018, five business days after the fully executed agreement. Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license.
Quebec is considered the optimal locale for an ACMPR for many reasons. The province is host to 20% of Canada’s population and has only had two ACMPR licenses approved to date with only one currently producing. Quebec is currently vastly under represented relative to many other provinces in Canada. The Quebec government has always maintained an aggressive approach to attaining 25% of whatever Canada’s intentions are with business. Specifically regarding ACMPR licenses, Quebec has publicly stated they want Health Canada to process all 16 of the license applications in Quebec and have them approved expeditiously. When it comes time for Quebec licensees to purchase their supply, they will have a high priority on purchasing from Quebec growers. In Canada there are many politicians who act on the premise that Quebec deserves continual special policy treatment and defenders of the foregoing justify the exceptions with an observation that French language and culture in Quebec makes that province unique; that merits special treatment.
Alliance Growers will immediately acquire the Quebec late stage licensed producer applicant, with payments issued in stages. The terms of the BiocannaTech acquisition are as follows:
A down payment of $238,637, which has been paid.
a) The issuance of $50,000 in shares to Canna Technology Inc. and 1,200,000 shares to 1134778 BC Ltd (5/6) and Erick Factor (1/6) (“the Recipients”) will take place within five days following execution of the purchase agreement and filing with the CSE;
b) $250,000 in shares to Canna Technology and 1,200,000 shares to the Recipients to be released immediately upon receipt of Health Canada approval for Ready to Build stage on or before December 31, 2019;
c) $500,000 paid to Canna Technology and 1,200,000 shares to the Recipients upon receipt of municipal building permits to start construction on or before December 31, 2019;
d) $500,000 in shares to Canna Technology and 1,200,000 shares to the Recipients upon receipt of Health Canada approval of Cultivation stage on or before December 31, 2019;
e) $500,000 in shares to Canna Technology and 1,200,000 shares to the Recipients upon receipt of Health Canada LP License on or before December 31, 2019.
The initial BiocannaTech facility is configured at 10,000 sq. ft. and is attached to a 120,000-sq. ft. warehouse to provide for phased expansion. BiocannaTech will have the capacity to produce up to 1,000 kg per year initially and be able to increase that output in subsequent phases of expansion. The building is in the Town of Mount Royal (“T.M.R.”) in Montreal. This site is zoned for Medical Cannabis Production and BiocannaTech has the confirmation letter from the city of T.M.R. It is important to note that the lease provides the option to buy the facility and build equity for Alliance Growers and its shareholders.
Commenting on execution of the final agreement to acquire BiocannaTech, Dennis Petke, Alliance Growers’ President and CEO, stated “We are very pleased to finalize this important and exceptional opportunity to acquire BiocannaTech for Alliance Growers and the Company’s shareholders. We are fortunate to have financing support from the partnerships we have developed over the past 12 months. In December of 2017 and earlier this year, Alliance Growers finalized funding of over $1M from a private placement and the exercise of warrants and options. Upon conclusion of a small financing in April, we expect to complete a larger financing in May for up to $10 Million. Alliance Growers will then be moving full steam ahead on financing the “initial build stage” of BiocannaTech to create a premier cannabis supplier in Quebec. Management of Alliance Growers believes it is advantageous to capitalize on the governmental goal to increase the number of ACMPR licensed companies in Quebec. We are pleased to have now entered the grow space in Quebec whilst we negotiate additional license applicants in the province. These are exciting times for the cannabis industry and especially for Alliance Growers as we execute on our additional plans including further acquisitions of interests in ACMPR applicants, development of the Canna-App and finalization of the Company’s Pharmaceutical Grade CDB Oil partnership with an Israeli Medical Cannabis Company. We ask all stakeholders to watch for news on further developments of the Cannabis Botany Centre as well. We also look forward to becoming a preferred tissue cultured plantlet supplier through the partnership we are developing with Pharmagreen on the Cannabis Botany Centre, to not only the Quebec ACMPR community but right across Canada.”
About Alliance Growers
Alliance Growers is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan — Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.
Alliance Growers is working with WFS Pharmagreen Inc. advancing a new business partnership, to jointly develop and operate a 40,000-square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.
Alliance Growers has signed a fully executed agreement to acquire a licensed producer applicant, BiocannaTech, to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec. Closing is on or before five business days after the fully executed agreement. Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license. This acquisition allows the Company an opportunity to become a licensed producer in the Province of Quebec and gain an in-road to provide tissue culture plantlets to all licensed producers in Quebec.
Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.
If you would like to be added to Alliance Growers’ news distribution list, please send your email address to email@example.com
On behalf of the board of directors of
ALLIANCE GROWERS CORP.
President and CEO
For more information contact:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.
Expanding offering of traditional and cannabinoid-infused beverages and natural products through four major sales channels to reach growing consumer base
Diversified health and wellness; beverage and natural products company, BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide an outlook on its strategic evolution into a diversified health & wellness beverage and natural products company.
Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant” or the “Company”) is pleased to announce the appointment of Gabriel Villablanca as its Vice President of Marketing. Villablanca previously held the position of Director of eCommerce and will assume duties as VP of Marketing immediately. In this role, he will be responsible for leading marketing strategy as Better Plant’s brands continue to expand.
Koios has engaged NewAge, a Denver-based distributor of beverages and snacks, to carry its KOIOS™ nootropic beverages and Fit Soda™ functional beverages throughout Colorado and potentially in other markets. Koios anticipates that NewAge’s in-depth knowledge of functional beverages, in addition to its significant footprint in Colorado can complement Koios’ existing presence in the state and potentially create new opportunities for the Company.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that it has entered into a distribution agreement with NewAge, Inc. (“NewAge”) (NASDAQ: NBEV), a major omnichannel wholesaler of beverages and snacks. Based in Denver Colorado, NewAge provides direct store delivery (“DSD”) service for beverage brands all across the state of Colorado, primarily in the Front Range region. Koios believes its engagement with NewAge can strengthen the Company’s existing presence in Colorado, which benefits from Koios’ prestige as a local business. NewAge will distribute all of Koios’ beverage products including KOIOS™ nootropic beverages and Fit Soda™ functional beverages (collectively, the “Koios Beverages”). In 2021 the Company announced several placements of Koios Beverages in local grocery chains in regions to include New England Utah Oregon Louisiana Massachusetts and California in addition to a placement of Fit Soda ™ in over 100 HEB supermarkets in Texas announced in November 2020. With approval for Koios Beverages to be sold through the NewAge distribution network, new placements could be finalized much more rapidly and enable the Company to further grow its base of more than 4,000 points of sale in the United States.
Company anticipates escalation in cultivation to have direct effect on revenue growth
TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (OTC: TCNAF) (“TransCanna” or the “Company”) has increased its cultivation capacity by 300%, enabling it to effectively triple production of its most profitable and in-demand product: exotic indoor flower. With this increased cultivation capacity, Lyfted Farms – hailed in the industry for its premium genetics and seasoned team of master cultivators – can now meet consumer-driven demand in Northern California while expanding into the sizable Southern California home containing over 23,000,000 residents.